Facebook Pixel

Cervarix Induces Stronger Immune Response Than Gardasil: Study

Rate This

A head-to-head comparison suggests that GlaxoSmithKline PLC's Cervarix vaccine triggers a stronger immune response against the cervical cancer-causing human papillomavirus (HPV) than Merck & Co.'s Gardasil.

The Glaxo-funded study of 1,100 women, ages 18 to 45, didn't examine which vaccine was more effective at preventing cervical cancer or precancerous lesions, the Wall Street Journal reported.

The findings were presented at a Swedish medical conference that began Friday. Cervarix is on the market in Europe and is currently under review by the U.S. Food and Drug Administration.

Gardasil is designed to protect women against four HPV types, including those that cause most cases of genital warts, the Wall Street Journal reported. Cervarix targets two HPV types and isn't meant to provide as much protection against genital warts.

Add a CommentComments

There are no comments yet. Be the first one and get the conversation started!

Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy

Sexually Transmitted Diseases

Get Email Updates

Sexually Transmitted Diseases Guide

Have a question? We're here to help. Ask the Community.


Health Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER - for free!